HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mycobacterium tuberculosis - atpE gene profile of bedaquiline-treated pulmonary tuberculosis patients at the referral hospital Dr. Soetomo, Indonesia.

AbstractBackground:
The atpE gene is a target for bedaquiline (Bdq)-activating drug action and mutations in the gene are fixed to cause resistance. However, changes in the amino acid of ATPase have been little reported from a clinical setting since it was first used in 2015 in Indonesia. This study aims to observe the sequence of nucleotide and amino acid from rifampicin-resistant (RR) pulmonary tuberculosis (TB) patients, both new and relapse cases treated with Bdq.
Methods:
This is an observational descriptive study performed in the referral hospital Dr Soetomo, Indonesia, at August 2022-November 2022. We performed Sanger sequencing and comparison of the atpE gene from the patient's sputum from August to November 2022 to wild-type Mycobacterium tuberculosis H37Rv and species of mycobacteria using BioEdit version 7.2 and BLAST NCBI software. We also conducted an epidemiological study on patients' characteristics. This study uses a descriptive statistic to show the percentage of data.
Results:
The total of 12 M. tuberculosis isolates showed that the atpE gene sequence was 100% similar to the wild-type M. tuberculosis H37Rv. No single-nucleotide polymorphisms or mutations were found, and no change in the amino acid structure at position 28 (Asp), 61 (Glu), 63 (Ala), and 66 (Ile). The percentage identity of atpE to M. tuberculosis H37Rv and M. tuberculosis complex was 99%-100%, while the similarity with the other mycobacteria species other than TB (Mycobacterium avium complex, Mycobacterium abscessus, and Mycobacterium lepraemurium) was 88%-91%.
Conclusions:
This study revealed M. tuberculosis -atpE gene sequence profile of RR-TB patients had no mutations, as the specific gene region, and no change in the amino acid structure. Therefore, Bdq can be continually trusted as an effective anti-tubercular drug in RR-TB patients.
AuthorsMuhamad Frendy Setyawan, Ni Made Mertaniasih, S Soedarsono, Zakiyathun Nuha, Yustinus Maladan, Sohkichi Matsumoto
JournalInternational journal of mycobacteriology (Int J Mycobacteriol) 2023 Apr-Jun Vol. 12 Issue 2 Pg. 122-128 ISSN: 2212-554X [Electronic] India
PMID37338471 (Publication Type: Observational Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • bedaquiline
  • Antitubercular Agents
  • Nucleotides
Topics
  • Humans
  • Mycobacterium tuberculosis
  • Antitubercular Agents (pharmacology, therapeutic use)
  • Indonesia
  • Tuberculosis, Pulmonary (drug therapy, microbiology)
  • Tuberculosis, Multidrug-Resistant (drug therapy)
  • Nucleotides (pharmacology)
  • Microbial Sensitivity Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: